Iovance Biotherapeutics
IOVA
12.92
-0.05
-0.35%
Iovance Biotherapeutics
US · IOVA
#1864 by market cap
Listed 1970
12.92
-0.05
-0.35%
Live - 5344 symbols - heartbeat 566s ago
· 2026-10-08 08:19
Pre-market
12.78
-1.05%
After-hours
12.88
-0.27%
Overnight
12.94
+0.19%
- Market cap
- 5.85B
- P/E (TTM)i
- -18.72
- P/Bi
- 7.95
- EPSi
- -1.09
- Div yieldi
- 0.00%
- 52W posi
- 82%
Reader sentiment
Are you bullish or bearish on IOVA?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 7 analysts
Buy
Avg price target
14.71 +13.9%
Price target rangecurrent 12.92
Low8.00
Avg14.71
High20.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-30 | Wells Fargo | -- | BUY | 18.00 |
| 2026-09-30 | H.C. Wainwright | -- | BUY | 20.00 |
| 2026-09-29 | TD Cowen | -- | BUY | 16.00 |
| 2026-09-29 | Wells Fargo | -- | BUY | 18.00 |
| 2026-09-29 | H.C. Wainwright | -- | BUY | 20.00 |
| 2026-09-29 | Barclays | -- | BUY | 15.00 |
| 2026-09-24 | Goldman Sachs | -- | BUY | 15.00 |
| 2026-09-17 | Barclays | -- | BUY | 15.00 |
| 2026-08-25 | TD Cowen | -- | BUY | 10.00 |
| 2026-08-17 | Mizuho Securities | -- | BUY | 11.00 |
| 2026-08-07 | Citizens JMP | -- | BUY | 8.00 |
| 2026-08-07 | Barclays | -- | BUY | 13.00 |
| 2026-08-06 | H.C. Wainwright | -- | BUY | 9.00 |
| 2026-07-20 | Barclays | -- | BUY | 11.00 |
| 2026-06-22 | Mizuho Securities | -- | BUY | 10.00 |
| 2026-06-04 | H.C. Wainwright | -- | BUY | 9.00 |
| 2026-06-02 | Barclays | -- | BUY | 11.00 |
| 2026-06-01 | H.C. Wainwright | -- | BUY | 9.00 |
| 2026-05-22 | H.C. Wainwright | -- | BUY | 9.00 |
| 2026-05-08 | Barclays | -- | BUY | 11.00 |
| 2026-05-07 | TD Cowen | -- | BUY | 5.00 |
| 2026-05-07 | H.C. Wainwright | -- | BUY | 9.00 |
| 2026-04-22 | H.C. Wainwright | -- | BUY | 9.00 |
| 2026-04-20 | Barclays | -- | BUY | 11.00 |
| 2026-02-25 | Wells Fargo | -- | BUY | 14.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Strong Buy
Analyst consensus
Buy
All 2 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 1 upgrade vs 0 downgrades among tracked analyst rating changes.
- Most recent: Goldman Sachs moved from Sell to Buy on 2026-09-24.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-09-24 | Goldman Sachs | SELL → BUY | 15.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-06 | -- | ±29.65% | +43.09% (beat) |
| 2026/Q1 | 2026-05-07 | -- | ±15.83% | -13.20% (in line) |
| 2025/Q4 | 2026-02-24 | -- | ±18.34% | +30.80% (beat) |
| 2025/Q3 | 2025-11-06 | -- | ±24.86% | +27.62% (beat) |
| 2025/Q2 | 2025-08-07 | After close | ±34.92% | -20.08% (in line) |
| 2025/Q1 | 2025-05-08 | After close | ±27.44% | -44.80% (beat) |
| 2024/Q4 | 2025-02-27 | After close | ±25.10% | -19.49% (in line) |
| 2024/Q3 | 2024-11-07 | After close | ±19.14% | -13.80% (in line) |
| 2024/Q2 | 2024-08-08 | After close | ±29.91% | +24.94% (in line) |
| 2024/Q1 | 2024-05-09 | After close | ±17.71% | -18.48% (beat) |
| 2023/Q4 | 2024-02-28 | After close | ±11.80% | -8.72% (in line) |
| 2023/Q3 | 2023-11-07 | After close | ±24.75% | -3.47% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 08:19:57 · For reference only, not investment advice and not tailored to your situation.